The National Institutes of Health is funding a research study that hopes to identify the first drugs that can treat the condition of chronic depression with hyperkalmia.

The study is being funded by the National Institute of Mental Health.

The new study will test the potential of a synthetic peptide called S-Methylcysteine that is known to act as a precursor to the serotonin-reuptake inhibitor (SSRI).

The drug has been shown to decrease the activity of the serotonin transporter in mice, which is the part of the brain that regulates the actions of the neurotransmitters in the brain.

S-Mec is a compound that binds to the neurotransmitter serotonin.

It binds to serotonin in the body by binding to the receptor for serotonin called 5-HT1A.

The compound then works to regulate the activity and activity of serotonin.

In addition to its potential to reduce the amount of serotonin that the brain needs, the new study is also working to find a treatment that can help with symptoms of depression, like increased anxiety, irritability, and depression.

The treatment could also help with the symptoms of Alzheimer’s disease, and potentially other conditions.

The study is part of a larger effort to develop treatments for depression.

Currently, scientists have developed therapies to treat anxiety disorders, depression, and PTSD.

But none of these drugs are FDA approved, and they are usually given in pill form.

This new study aims to create a drug that can act as an alternative to SSRIs in treating chronic depression, the study authors wrote in the New England Journal of Medicine.

The drug could potentially be available in the future, though there is currently no FDA approval for it.

The research was funded by a National Institutes, or NIH, Office of Biological Sciences (OBSP) grant and the Office of Chemical Dependence Research, a division of the NIH.

The National Science Foundation also provided support for the study.

The team is working to develop a synthetic version of S-methylcysteina that is similar to the molecule that is in the human brain, the researchers wrote in their paper.

Smethylcystine binds to a protein called a serotonin transporter and is known as a drug-drug interconversion, or DDI.

It acts as a transporter for serotonin and a receptor for dopamine.

The DDI protein is also found in the neurons of the human heart.

Sethylcystines function as a ligand for the serotonin receptor, and when the receptor is upregulated, S-mec acts as an agonist.

S-met has also been shown in other studies to increase the activity or inhibit the activity, or increase the release of dopamine in the brains of mice.

Smet acts by blocking a specific transporter called the serotonin 1A receptor, which allows the DDI to bind to the receptors for serotonin.

When the serotonin 2A receptor is activated, Smet acts as the antagonist.

This causes the DIE to bind and prevent the receptor from becoming activated.

The S-Met compound has been used in trials to treat depression in humans, but there have been no significant benefits.

In the new NIH-funded study, the investigators found that S-MET was able to decrease depressive symptoms and increase serotonin in animals.

In mice, the S-MTI-treated animals exhibited increased anxiety and reduced depressive symptoms.

The researchers also found that the drug decreased the activity in the hippocampus of the mice.

They also found decreased inflammation in the animals.

Sketches of the SMET molecule in the mouse brain.

Smet increases the activity levels of serotonin transporter proteins in the prefrontal cortex.

The SMET also blocks the serotonin reuptake transporter protein in the amygdala.

This pathway allows the brain to process stress and anxiety, but it also promotes the production of new dopamine.

The researchers hope that their study will pave the way for more effective drugs that will have the ability to improve depressive symptoms, the authors wrote.

The drug could also be effective for treating hyperkalaemia, which can cause damage to the blood vessels in the heart.

This condition can also lead to cardiac arrest, a condition in which the heart stops beating, which may lead to a death.

Hyperkalaemic individuals can be treated with medication, but the treatments typically have side effects that are not considered to be life-threatening, such as heart failure and heart attacks.

SMET could be effective in treating depression and hyperkalyemia, as well as anxiety and other symptoms.